Showing 161 - 180 results of 502 for search '"Utrecht"', query time: 0.05s Refine Results
  1. 161
  2. 162

    Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

    Published 2025-02-01
    “…The coprimary endpoints are disease activity and quality of life across and within each disease.Ethics and dissemination The study received approval from the Medical Research Ethics Committee in Utrecht, Netherlands. A Data Safety Monitoring Board has been established to monitor the trial’s safety and progress.Trial registration number NCT06285539.…”
    Get full text
    Article
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180